Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Five-year-old human brain organoids aged on schedule
The cultured spheres typically mimic only prenatal development, but the five-year-old ones grown in Paola Arlotta’s lab acquired postnatal features.
Five-year-old human brain organoids aged on schedule
The cultured spheres typically mimic only prenatal development, but the five-year-old ones grown in Paola Arlotta’s lab acquired postnatal features.
Marco Facchin explores the ever-shifting landscape of neuroscience theory and philosophy
Computational explanations of cognition, though powerful, aren't the only game in town.
Marco Facchin explores the ever-shifting landscape of neuroscience theory and philosophy
Computational explanations of cognition, though powerful, aren't the only game in town.
Brainstem neurons add new element to ‘already complex’ anxiety circuitry
Precise optogenetic modulation of a medullary neuron population reveals their role in anxiety-like behaviors.
Brainstem neurons add new element to ‘already complex’ anxiety circuitry
Precise optogenetic modulation of a medullary neuron population reveals their role in anxiety-like behaviors.